<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953498</url>
  </required_header>
  <id_info>
    <org_study_id>AFSSAPS A70516-50</org_study_id>
    <nct_id>NCT00953498</nct_id>
  </id_info>
  <brief_title>Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins</brief_title>
  <official_title>Influence of Glitazones on the Vasodilatory Effect of HDL Lipoproteins and on Phospholipase A2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HDL from patients with type 2 diabetes show a significant reduction of their&#xD;
      endothelium-dependent vasodilatory effect.&#xD;
&#xD;
      The primary objective of the study is to analyze whether treatment with glitazones&#xD;
      (pioglitazone and rosiglitazone)may improve the endothelium-dependent vasodilatory effect of&#xD;
      HDL lipoproteins in patients with type 2 diabetes.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  to analyze the effect of glitazone treatment on phospholipase A2&#xD;
&#xD;
        -  to look for possible differences between the effects of pioglitazone and those of&#xD;
           rosiglitazone&#xD;
&#xD;
        -  to analyze the glycemic response to glitazone therapy according to clinical and&#xD;
           biological baseline characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed as follows:&#xD;
&#xD;
      At baseline, before initiating glitazone treatment, clinical data will be recorded and blood&#xD;
      samples will be obtained for biological measurements (blood glucose, HbA1c, total&#xD;
      cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, liver enzymes), phospholipase&#xD;
      A2 measurement and the study of the vasodilatory effect of HDL particles.For this purpose, we&#xD;
      will study,using rabbit aorta rings,the ability of HDL to suppress the inhibition of&#xD;
      vasodilation that is induced by oxidised LDL.&#xD;
&#xD;
      For all the patients included into the study, a treatment by pioglitazone (at an initial dose&#xD;
      of 30 mg/day) or rosiglitazone (at an initial dose of 4 mg/day) will be given by&#xD;
      randomization.&#xD;
&#xD;
      A visit will be performed at week 12, in order to titrate the glitazone dose (up to 45 mg/day&#xD;
      for pioglitazone, up to 8 mg/day for rosiglitazone)according to HbA1c level and values of&#xD;
      self-monitoring blood glucose.&#xD;
&#xD;
      At week 24, the last visit will take place. During this visit, clinical data will be recorded&#xD;
      and blood samples will be obtained for biological measurements (blood glucose, HbA1c, total&#xD;
      cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, liver enzymes), phospholipase&#xD;
      A2 measurement and the study of the vasodilatory effect of HDL particles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Action of glitazone on the endothelium-dependent vasodilatory effects of HDL lipoproteins</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of glitazone therapy on Phospholipase A2 level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the glycemic response to glitazones according to baseline clinical and biological characteristics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Look for possible differences between pioglitazone and rosiglitazone for their effects on HDL lipoproteins and phospholipase A2</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with rosiglitazone at a dose between 4mg and 8 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>After randomization, patients will be treated by pioglitazone or rosiglitazone</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>pioglitazone: ACTOS</other_name>
    <other_name>rosiglitazone: AVANDIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>treatment with rosiglitazone at a dose between 4mg and 8 mg/day</description>
    <arm_group_label>rosiglitazone</arm_group_label>
    <other_name>pioglitazone: ACTOS</other_name>
    <other_name>rosiglitazone: AVANDIA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with type 2 diabetes treated by oral antidiabetic agents (except glitazones)&#xD;
             and/or insulin&#xD;
&#xD;
          -  age&gt; 18 years&#xD;
&#xD;
          -  HbA1c &gt; 6.5%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  renal failure&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  primary hyperlipidemia&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  treatment that may modify lipid metabolism (glucocorticoids, oestrogens, retinoids,&#xD;
             HIV antiviral drugs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno L Vergès, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dijon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Endocrinologie-diabétologie, Hôpital du Bocage CHU</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Perségol L, Vergès B, Foissac M, Gambert P, Duvillard L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2006 Jun;49(6):1380-6. Epub 2006 Apr 5.</citation>
    <PMID>16596357</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>August 30, 2013</last_update_submitted>
  <last_update_submitted_qc>August 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Dijon</investigator_affiliation>
    <investigator_full_name>Prof. Bruno Vergès</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>glitazones</keyword>
  <keyword>HDL</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

